REG - ValiRx PLC - Grant of options <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

16/07/2015 13:00

RNS Number : 4364R
ValiRx PLC
29 June 2015
29 June 2015
ValiRx Plc
("ValiRx" or the "Company")
Grant of options
ValiRx Plc (AIM: VAL), the AIM-quoted life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 26 June 2015, it granted 1,221,560 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.
Name of director
Number of shares held
% of issued share capital
Number of existing options
Number of new options granted
Total options now held
Options held as % of issued share capital
Satu Vainikka
224,909
0.75%
472,000
222,000
694.000
2.3%
George Morris
188,287
0.62%
406,000
191,000
597,000
2.0%
Gerry Desler
141,875
0.47%
404,240
189,760
594,000
2.0%
Kevin Alexander
104,278
0.34%
371,200
173,800
545,000
1.8%
Oliver de Giorgio-Miller
59,555
0.2%
344,000
211,000
555,000
1.8%
Seppo Makinen
10,187
0.03%
224,000
105,000
329,000
1.1%
Total Directors
729,091
2.41%
2,221,440
1,092,560
3,314,000
11%







Other employees
 Nil
Nil
350,400
129,000
479,400
1.6%







Total
729,091
2.41%
2,571,840
1,221,560
3,793,400
12.6%
The new options were granted under the Company's stock option plan and have an exercise price of 51 pence. The new options are exercisable from 26 June 2015 until 25 June 2025.
Following the grant of the new options, the total number of Ordinary Shares under option held by directors, which could be issued, is 3,314,000 Ordinary Shares, representing approximately 11 per cent. of the current issued share capital of the Company.
In addition, a further 129,000 options have been granted to employees of the Company at an exercise price of 51 pence which are exercisable until 25 June 2025. 
The issued share capital of the Company comprises 30,177,214 ordinary shares of 0.1 pence each.
For more information, please contact:
ValiRx plc
Tel: +44 (0)20 3008 4416
Dr Satu Vainikka
www.ValiRx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0)20 7148 7900
Liam Murray / Avi Robinson



Northland Capital Partners (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell
John Howes / Abigail Wayne (Broking)



Peckwater PR
Tel: +44 (0)7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk
Notes for Editors 
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiFinn is the biomarkers and diagnostic development division
2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSGXGDLUXDBGUR